The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II randomized study of telaglenastat, a glutaminase (GLS) inhibitor, versus placebo, in combination with pembrolizumab (Pembro) and chemotherapy as first-line treatment for KEAP1/NRF2-mutated non-squamous metastatic non-small cell lung cancer (mNSCLC).
 
Ferdinandos Skoulidis
Honoraria - Bristol-Myers Squibb
 
Joel W. Neal
Honoraria - Biomedical Learning Institute; CME Matters; Medscape; MJH Life Sciences; MLI Peerview; Prime Oncology; Research to Practice; Rockpointe
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences; Exelixis; Genentech/Roche; Jounce Therapeutics; Lilly; Takeda
Research Funding - Adaptimmune (Inst); Boehringer Ingelheim (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Takeda (Inst)
Patents, Royalties, Other Intellectual Property - Up To Date - Royalties
 
Wallace L. Akerley
Consulting or Advisory Role - AstraZeneca; Calithera Biosciences
Research Funding - Bristol-Myers Squibb; Incyte; Loxo
 
Paul K. Paik
Honoraria - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Celgene; EMD Serono; Takeda
Research Funding - Celgene; EMD Serono
Travel, Accommodations, Expenses - EMD Serono
 
Thales Papagiannakopoulos
Stock and Other Ownership Interests - Mirati Therapeutics
Honoraria - Vividion Therapeutics
Consulting or Advisory Role - Calithera Biosciences
Research Funding - Agios; Dracen
 
Karen L. Reckamp
Consulting or Advisory Role - Amgen; ARIAD; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Calithera Biosciences; Euclises; Exelixis; Genentech; Guardant Health; Loxo; Precision Health Economics; Seagen; Takeda; Tesaro
Research Funding - Abbvie (Inst); ACEA Biosciences (Inst); Adaptimmune (Inst); ARIAD (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Guardant Health (Inst); Janssen Oncology (Inst); Loxo (Inst); Molecular Partners (Inst); Pfizer (Inst); Seagen (Inst); Xcovery (Inst); Zeno Pharmaceuticals (Inst)
 
Jonathan W. Riess
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Heron; Loxo; Medtronic; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Yonchu Jenkins
Employment - Calithera Biosciences; Secom Medical System (I)
Stock and Other Ownership Interests - Calithera Biosciences; Secom Medical System (I)
 
Sacha Holland
Employment - Calithera Biosciences
Stock and Other Ownership Interests - BerGenBio; Calithera Biosciences; Rigel; Roche/Genentech
Travel, Accommodations, Expenses - Calithera Biosciences
 
Francesco Parlati
Employment - Calithera Biosciences
Stock and Other Ownership Interests - Calithera Biosciences
 
Yijing Shen
Employment - Calithera Biosciences
Stock and Other Ownership Interests - Calithera Biosciences
 
Sam H. Whiting
Employment - Calithera Biosciences; Seagen (I)
Stock and Other Ownership Interests - Calithera Biosciences; Seagen (I)
 
Naiyer A. Rizvi
Leadership - ARMO BioSciences
Stock and Other Ownership Interests - ARMO BioSciences; Bellicum Pharmaceuticals; Brooklyn ImmunoTherapeutics; Gritstone Bio
Consulting or Advisory Role - Abbvie; Abbvie; AstraZeneca/MedImmune; Bellicum Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb; Editas Medicine; EMD Serono; Genentech/Roche; GlaxoSmithKline; Illumina; Janssen; Lilly; Merck Sharp & Dohme; NeoGenomics Laboratories; Novartis; Regeneron; Takeda
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme
Patents, Royalties, Other Intellectual Property - Royalties related to patent filed by MSKCC, Determinants of cancer response to immunotherapy (PCT/US2015/062208) licensed to Personal Genome Diagnostics